1st Counsel – Lifestyle
Author:
Reviva Pharmaceuticals
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
April 23, 2026
Reviva Announces Letter to Shareholders
April 15, 2026
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
March 30, 2026
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
March 23, 2026
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
March 18, 2026
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
March 18, 2026